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Summary 
We studied the role of the δ, µ, and к opioid receptor (OR) 
subtypes in the cardioprotective effect of chronic continuous 
normobaric hypoxia (CNH) in the model of acuteanoxia/ 
reoxygenation of isolated cardiomyocytes. Adaptation of rats to 
CNH was performed by their exposure to atmosphere containing 
12 % of O2 for 21 days. Anoxia/reoxygenation of cardiomyocytes 
isolated from normoxic control rats caused the death of 51 % of 
cells and lactate dehydrogenase (LDH) release. Adaptation of rats 
to CNH resulted in the anoxia/reoxygenation-induced 
cardiomyocyte death of only 38 %, and reduced the LDH release. 
Pre-incubation of the cells with either the non-selective OR 
blocker naloxone (300 nM/l), the δ OR antagonist TIPP(ψ)  
(30 nM/l), the selective δ2 OR antagonist naltriben (1 nM/l) or the 
μ OR antagonist CTAP (100 nM/l) for 25 minutes before anoxia 
abolished the reduction of cell death and LDH release afforded by 
CNH. The antagonist of δ1 OR BNTX (1 nM/l) or the κ OR 
antagonist nor-binaltorphimine (3 nM/l) did not influence the 
cytoprotective effects of CNH. Taken together, the cytoprotective 
effect of CNH is associated with the activation of the δ2 and μ OR 
localized on cardiomyocytes. 
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Introduction 
 
Acute myocardial infarction is a common 
cardiovascular disease with high mortality worldwide. 
Therefore, the protection of myocardium against ischemic 
injury remains a topical problem of the modern medicine. 
Investigation of the mechanisms underlying heart 
ischemic resistance that occurs naturally as a result of 
adaptive effects may allow us to determine the direction 
for the search for new cardioprotective pharmacological 
interventions (Heusch and Gersh 2017).  
To date, convincing evidence has accumulated 
indicating that hearts of rats exposed to chronic 
continuous normobaric hypoxia (CNH) become resistant 
to ischemia/reperfusion injury. Tajima et al. (1994) first 
showed that myocardium of rats adapted to CNH is better 
able to restore contractile function after ischemia than the 
non-adapted myocardium (Tajima et al. 1994). Number 
of subsequent studies confirmed cardioprotective effects 
of CNH in various in vivo and ex vivo experimental 
settings. CNH not only improves post-ischemic recovery 
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of heart function (Maslov et al. 2016), but it also reduces 
myocardial infarct size (Maslov et al. 2013, Chytilova  
et al. 2015, Naryzhnaya et al. 2015a) and exerts 
cytoprotective effects against simulated 
ischemia/reperfusion in isolated cardiomyocytes 
(Borchert et al. 2011, Naryzhnaya et al. 2015b).  
Although many factors and signaling pathways 
have been shown to play a role in CNH-induced 
cardioprotection, its detailed mechanism is still unclear. 
At present, there is reason to presume that intracellular 
oxygen sensor prolyl-4-hydroxylase (Semenza 2014), 
reactive oxygen species (Szarszoi et al. 2003),  
NO synthase (Alanova et al. 2015, Zaobornyj et al. 2009, 
2012), protein kinase C (Hlavackova et al. 2010),  
p38 MAP kinase (Milano et al. 2010, Ravingerova et al. 
2007), and AMP-activated protein kinase (Sukhodub  
et al. 2007) participate in the mechanism of cardio-
protection at chronic hypoxia. As a result of the work of 
these signaling pathways, transcription factors such as 
HIF-1α, NFκB and AP-1 are activated (Semenza 2009), 
and changes in the functioning of mitochondrial ion 
channels and mPTP lead to improved energy metabolism 
of mitochondria (Maslov et al. 2015) and their resistance 
to ischemia/reperfusion. 
Importantly, it has been established that the 
infarct size-limiting effect of CNH is mediated by 
activation of opioid receptors (OR), particularly δ2 and 
μ subtypes (Maslov et al. 2013). We have shown earlier 
that these OR also play a role in CNH-induced protection 
of the isolated perfused rat heart against ischemia and 
reperfusion (Maslov et al. 2015). Therefore, it can be 
argued that OR, which provide an adaptive increase in 
heart tolerance to the impact of ischemia and reperfusion, 
are localized in the heart. It is known that these receptors 
are located on the sarcolemma of cardiomyocytes and on 
the cell membrane of endothelial cells (Maslov et al. 
2016). Vascular smooth muscle cells also express δ OR 
(Maslov et al. 2016). Therefore, it has remained unclear 
whether OR on cardiomyocytes can mediate the 
protective effect of CNH. The purpose of this work was 
to examine the role of various OR subtypes in the 
cytoprotective effect of CNH using isolated rat 
ventricular myocytes subjected to acute 
anoxia/reoxygenation (A/R).  
 
Methods 
 
The experiments were carried out on male 
Wistar rats weighing 250-300 g. The animals were 
housed at 23±1 °C with a relative humidity of 60-70 % 
and a 12-h light/dark cycle with free access to water and 
standard rat chow. All procedures conformed to the 
Directive 2010/63/EU of the European Parliament and the 
Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). Ethical approval 
was granted by the Ethical Committee of Research 
Institute of Cardiology, Tomsk National Research 
Medical Center. 
 
Protocol of adaptation to hypoxia 
The animals were randomly divided into two 
groups. Control rats were kept in standard normoxic 
conditions. The animals of the experimental group (n=13) 
were exposed to CNH in the hypoxic chamber  
for 21 days as described previously (Neckar et al. 2017, 
Maslov et al. 2013). Concentrations of O2 (12 %) and 
CO2 (0.3 %) inside the hypoxic chamber were constantly 
maintained by the Bio-Nova-204G4R1 system (NTO 
Bio-Nova, Russia, Moscow) and monitored by the 
sensors TCOD-IR and OLC 20 (Oldham, France) via the 
MX32 control unit (Oldham, France); the temperature 
was maintained at 23±1 °C. The animals were removed 
from the hypoxic chamber 24 hours before the start of the 
experiment. Normoxic animals (n=11) were kept in room 
air for the same period of time.  
 
Isolation of cardiomyocytes and detection of 
anoxia/reoxygenation injury 
Isolation of ventricular myocytes and induction 
of A/Rwere carried out as described earlier (Borchert et 
al. 2011, Xuand Colecraft 2009, Bøtker et al. 2018). The 
animals were heparinized (1500 IU, intraperitoneally) and 
sacrificed by cervical dislocation. After sternotomy, the 
hearts were quickly excised and placed in the Tyrode 
buffer (4 °C) until stopped. The aorta was cannulated and 
fixed for retrograde (Langendorff) perfusion. The 
perfusion rate throughout the entire procedure was  
10 ml/min, the temperature was 37 °C, and all solutions 
were pre-saturated with 100 % O2. Hearts were perfused 
for 3 min with Tyrode buffer (mM/l): 140 NaCl, 5.4 KCl, 
1 Na2HPO4, 1 MgCl2.6H2O, 10 glucose, 5 HEPES, 
1 CaCl2, pH 7.4. This was followed by perfusion with 
calcium-free Tyrode buffer for 3 min. Subsequent 
perfusion was performed with a solution containing 
(mM/l): 140 NaCl, 5.4 KCl, 1 Na2HPO4, 1 MgCl2.6H2O, 
10 glucose, 5 HEPES, 1.6 g/l fatty acid free BSA, 
collagenase type II 335 U/ml (Worthington) and  
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XIV protease 0.230 g/l (Sigma) for 15-25 min until the 
myocardial softening. For the collagenase washout, the 
hearts were perfused with calcium-free Tyrode solution 
for 4 min. Ventricular myocardium was excised from the 
aorta and dispersed by stirring in 10 ml of calcium-free 
Tyrode buffer containing 10 mg/ml fatty acid free BSA. 
The resulting cell suspension was filtered through 
cheesecloth and precipitated at room temperature for 
5 min. The supernatant was removed, the settled 
cardiomyocytes were diluted with calcium-free Tyrode 
buffer to 350-400 thousand cells in 1 ml. For 
stabilization, the isolated cells were incubated for 1 h at 
a temperature of 28 °C under the 5 % CO2 flow in the 
MCO-5AC CO2 incubator (SANYO, Japan). 
After the incubation, the survival of the cells was 
monitored by staining with trypan blue. The percentage 
of the dead (stained) cells and the viable rod-shaped 
cardiomyocytes (with the ratio of length-to-width not less 
than 3:1) were counted. In each sample, about 200 cells 
in total were analyzed in non-overlapping visual fields 
using light microscopy at × 100 magnification (Axio 
Observer Z1 microscope, Carl Zeiss Surgical GmbH, 
Germany) (Borchert et al. 2011, Skyschally et al. 2018). 
The initial survival rate of 50 % or more of the  
rod-shaped cardiomyocytes was considered suitable for 
the study. In the incubation medium of the cells, the 
activity of the marker of cardiomyocyte necrosis, lactate 
dehydrogenase (LDH), was determined after anoxia and 
after reoxygenation using Fluitest LDH-L kit (Analytical 
biotechnologies AG, Germany) and the 
spectrophotometer Infinite 200M (Tekan, Austria). The 
yield of LDH was calculated as a percentage of the total 
LDH activity, which was measured in pre-lyzed 
cardiomyocytes. For lysis, the cells were incubated for 
45 min at 37 °C with Triton X-100 at a concentration of 
12 μl/ml, centrifuged for 1 min at 10,000 g, and the total 
LDH activity was measured in the supernatant as 
described above. 
 
Experimental Protocol 
The cells were divided into 7 groups before the 
induction of anoxia. One of the following antagonists was 
added to the medium 25 min before the onset of anoxia: 
the non-selective OR antagonist naloxone (300 nM) 
(Lasukova et al. 2014, Alexander et al. 2017), the 
selective δ OR antagonist TIPP(ψ) (30 nM) (Martin et al. 
2001), the selective δ1 OR antagonist BNTX (1 nM) 
(Zeng et al. 2011), the selective δ2 OR antagonist 
naltriben (1 nM) (Zhu et al. 2009), the selective μ OR 
antagonist CTAP (100 nM) (Devidze et al. 2008), or the 
selective κ-OR antagonist nor-binaltorphimine (3 nM) 
(Stevens et al. 2000). Another groups of cells that were 
not treated with any OR antagonist served as controls. 
The cells of each group were divided into two 
sub-groups prior to the induction of anoxia. One of them 
was incubated in a modified Krebs buffer (anoxic buffer) 
containing (in mM/l): 118 NaCl, 25 NaHCO3, 4.7 KCl, 
1.2 MgSO4, 1.2 KH2PO4, 5 2-deoxyglucose, pH 7.4. To 
prevent access of oxygen, the surface of the suspension 
was layered with 5 - 6 drops of mineral oil (Vander Heide 
et al. 1990). The cells were subjected to anoxia for  
20 min at room temperature. After termination of anoxia, 
the cells were carefully pipetted through the oil and 
centrifuged for 1 min at 800 g. The supernatant was 
carefully removed and used to determine  
LDH concentration. The reoxygenation of the 
cardiomyocytes was carried out by placing them in the 
calcium-free Tyrode buffer for 30 min. At the end of the 
reoxygenation, cell survival was monitored and the  
LDH release was measured as described above. 
Corresponding sub-groups of the cells were resuspended 
in calcium-free Krebs buffer containing (mM/l):  
118 NaCl, 25 NaHCO3, 11 glucose, 4.7 KCl, 1.2 MgSO4, 
1.2 KH2PO4; pH 7.4 for 20 min at room temperature, then 
cells were centrifuged for 1 min at 800 g, supernatant was 
removed and used to determine LDH, and cells were 
incubated in calcium-free Tyrode buffer for 30 min. 
These sub-groups were used as controls for each group of 
cells subjected to A/R. Cell death during A/R was 
expressed as a percentage of controls not exposed to A/R.  
 
Statistical Analysis 
Results are expressed as mean ± SEM from 
indicated number of experiments. Data analysis was 
performed using STATISTICA 10. Two-way ANOVA 
followed by Dunnett's post hoc test was used to detect 
statistically significant differences between the groups. 
The limit of statistical significance was P<0.05. 
 
Results 
 
The effect of chronic normobaric hypoxia on 
anoxia/reoxygenation injury of isolated cardiomyocytes  
The initial survival of rod-shaped 
cardiomyocytes from control normoxic rats and from rats 
adapted to CNH was 65 % and 66 %, respectively. The 
number of dead cardiomyocytes after A/R was 51 % in 
the normoxic group, while A/R caused the death of only 
 
248   Naryzhnaya et al.  Vol. 68 
 
 
Fig. 1. Cardiomyocytes death during 
anoxia/reoxygenation (mean ± SEM). 
□ normoxia, n=11; ■ continuous 
normobaric hypoxia (CNH), n=13; 
*р<0.05 versus normoxic group; 
†р<0.05 versus untreated CNH 
group. All OR antagonists were 
added 25 min before the onset of 
anoxia. 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Lactate dehydrogenase 
(LDH) release from cardiomyocytes 
during anoxia (A) and LDH release 
during reoxygenation (B) (mean ± 
SEM). □ normoxia, n=11; ■ conti-
nuous normobaric hypoxia (CNH), 
n=13; *p<0.05 versus normoxic 
group; †p<0.05 versus untreated 
CNH group. All OR antagonists were 
added 25 min before the onset of 
anoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 % of the cells from the CNH group (Fig. 1). The 
release of LDH by cardiomyocytes from normoxic rats 
during anoxia and LDH release during reoxygenation was 
43.57 mU/l and 61.25 mU/l, respectively (i.e. 174 % and 
182 %, respectively, of control cells not subjected to 
(A/R). In the CNH group, this marker of cell injury 
dropped to 32.42 mU/l after anoxia and to 49 mU/l after 
A/R (i.e. 142 % and 138 %, respectively, of control CNH 
cells not subjected to A/R) (Fig. 2). 
These data indicate a marked cytoprotective 
effect of CNH. 
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The effects of OR antagonists on cytoprotection by 
chronic normobaric hypoxia 
As follows from Fig. 1 and 2, the addition of OR 
antagonists to the incubation medium of cardiomyocytes 
isolated from the normoxic rats did not cause a significant 
change in their survival and LDH release during A/R 
compared to the untreated controls. In contrast, 
incubation of the cardiomyocytes from CNH rats with the 
non-selective OR antagonist naloxone resulted in  
a decrease of cell survival rate after A/R that did not 
differ from naloxone-treated cells from normoxic group 
(Fig. 1). As shown in Fig. 2, naloxone had no significant 
effect on LDH release during anoxia, but it abolished the 
protective effect of CNH on LDH release during 
reoxygenation. These results suggest that the protective 
effect of CNH during reoxygenation (but not during 
anoxia) of isolated cardiomyocytes is mediated by the 
activation of OR. 
Addition of the selective µ OR antagonist CTAP 
to the medium of cardiomyocytes isolated from rats 
adapted to CNH resulted in increased number of dead 
cells after A/R from 38 % to 46 % (Fig. 1) and increased 
LDH release by 27 % compared to untreated CNH group 
(Fig. 2). The absence of the protective effect of CNH in 
the cells which were treated with CTAP suggests that  
µ OR play a role in CNH-induced cytoprotection.  
The δ OR inhibitor TIPP(ψ) and the selective 
inhibitor of δ2 OR naltriben attenuated the protective effect 
on cell viability and increased the LDH release during A/R 
in the CNH group compared to untreated cells (Fig. 1, 2). 
This effect was not observed during anoxia (Fig. 2). These 
data suggest that activation of δ2 OR at reoxygenation 
contributes to the cytoprotective effects of CNH. 
Treatment of cells with the δ1 OR antagonist 
BNTX or the κ OR antagonist nor-binaltorphimine did 
not exhibit any significant effect on improved cell 
survival and reduced LDH release during A/R in 
cardiomyocytes from rats adapted to CNH (Fig. 1, 2).  
 
Discussion 
 
It is well known that activation of OR results in 
cardioprotection against acute ischemia/reperfusion injury 
(Maslov et al. 2016, Heusch 2015, Headrick et al. 2015, 
Fraessdorf et al. 2015, Xu et al. 2015). Regarding the role 
of OR subtypes, it has been found that δ OR agonists have 
protective effect in the isolated rat heart (Karck et al. 2001, 
Maslov et al. 2006, Lasukova et al. 2014). Moreover, 
opioid TAN-67 increased cardiac tolerance to ischemia and 
reperfusion via δ1 OR occupancy (Huh et al. 2001). We 
have studied the effects of μ OR activation on the rat heart 
tolerance to ischemia and reperfusion (Lasukova et al. 
2015). Stimulation of μ OR in vivo by intraperitoneal 
administration of selective agonist DAMGO (0.1 mg/kg) 
reduced creatine kinase release from the isolated heart 
during reperfusion following global ischemia. Recently, 
Zhang et al. (2016) have shown that the selective µ2 OR 
agonist endomorphin-1 increases cardiac tolerance to 
reperfusion injury after regional ischemia. In addition, it 
has been demonstrated that the infarct reducing effect of 
Eribis Peptide 94 is mediated via µ OR occupancy (Gross 
et al. 2012). 
It has been well established that OR are one of 
the key links in the mechanism of transient 
cardioprotective effect of ischemic preconditioning 
(Heusch 2015, Fraessdorf et al. 2015, Xu et al. 2015, 
Schulz et al. 2001). The study of the infarct-limiting 
effect of preconditioning has revealed that this 
phenomenon is mediated by the activation of δ1 OR, 
whereas δ2 OR are not involved (Schultz et al. 1998). In 
contrast, others have reported the participation of κ OR, 
rather than δ1 OR, in the protective effect of 
preconditioning (Wang et al. 2001). The involvement of δ 
and κ OR in the cardioprotection induced by remote 
ischemic preconditioning has also been demonstrated 
(Surendra et al. 2013). In addition, we previously 
reported the involvement of µ, but not δ OR, in the 
antiarrhythmic effect of intermittent stress exposures 
(Maslov et al. 2004). Activation of µ and δ OR is also 
involved in the infarct sparing effect of postconditioning 
in vivo (Zatta et al. 2008). Last but not least, we found 
that the δ1 OR, but not µ and κ OR, are involved in 
cardioprotective effect of postconditioning in vitro 
(Lasukova et al. 2014, 2016). 
The above-mentioned studies allowed us to 
assume the possibility of participation of the opioidergic 
system in adaptation to hypoxia. Our findings that CNH 
of rats increased concentrations of endogenous δ and  
µ OR agonists met-enkephalin and endomorphins in 
plasma and myocardium support this hypothesis (Maslov 
et al. 2013). In addition, an increase in expression of the 
gene encoding δ OR was detected in the brain of mice 
after a 7-day normobaric hypoxia (Mayfield et al. 1996). 
We have found earlier that CNH protected rat hearts 
against post-ischemic contractile dysfunction and 
attenuated the depression of mitochondrial respiration 
and calcium retention capacity, and all these beneficial 
effects were dependent on the activation of OR (Maslov 
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et al. 2015). Moreover, the infarct size-limiting effect of 
CNH in vivo did not manifest following the blockade of µ 
or δ2 OR (Maslov et al. 2013). These data unequivocally 
indicate that the opioidergic system undergoes significant 
changes in the course of chronic hypoxia. 
The main finding of the present study is that the 
blockade of δ2 or µ OR, but not δ1 and κ OR, abolished 
the cytoprotective effect of CNH against A/R injury of 
isolated ventricular myocytes (Fig.1, 2). These data 
support our previous finding and allow us to conclude 
that the cardioprotective effect of CNH is mediated 
through the activation of δ2 and µ OR located on the 
sarcolemma of cardiomyocytes (Maslov et al. 2013, 
Sobanski et al. 2014, Ventura et al. 1990).  
Our present data indicating an important role of 
δ2 and µ OR in the cytoprotection induced by CNH are 
aparently in a contradiction with the above-mentioned 
reports, which analyzed the involvement of OR subtype 
in salutary effects of conditioning. We can assume that 
the differences in the role of OR subtypes in the 
mechanisms of various adaptive protective interventions 
studied on experimental models in vivo or in vitro may be 
due to the differences in the expression of different 
subtypes of OR on the sarcolemma of cardiomyocytes 
and on other types of cells. This hypothesis has yet to be 
investigated. The controversies over the involvement of 
different OR in cardioprotection may be also related to 
the fact that most of the endogenous opioids have low 
receptor selectivity. For example, enkephalins have  
a high affinity for µ and δ OR (Cox et al. 2015). Relative 
receptor selectivity has only been confirmed for 
endomorphins that have an affinity predominantly to  
µ OR (Feng et al. 2012). The low receptor specificity of 
endogenous opioids is accompanied by a similarity of 
molecular structure and intracellular signaling mechanism 
coupled to μ, δ and κ OR (Feng et al. 2012). 
Nevertheless, the data accumulated to date are sufficient 
to consider the opioidergic system as an important player 
in the regulation of survival of cardiomyocytes during 
hypoxic and ischemic insults.  
However, it remains unclear why the protective 
effect of CNH during anoxiadoes not depend on the 
activation of OR, while these receptors mediate the 
protection of cardiomyocytes during reoxygenation. Our 
results are in agreement with the data of Cao et al. (2003) 
who did not find any effect of met-enkephalin and 
dynorphin on the death of cardiomyocytes during anoxia, 
whereas a pronounced dose-dependent cytoprotective 
effect of these peptides was detected during 
reoxygenation (Cao et al. 2003). Obviously, the 
protective effect of CNH during anoxia is due to other 
mechanisms not associated with OR. 
In conclusion, the results of our study indicate 
the involvement of µ and δ2 opioid receptors of 
cardiomyocytes in the cell protection during 
anoxia/reoxygenation afforded by the chronic continuous 
normobaric hypoxia. 
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